by Dr. Gearóid Tuohy Dear EURETINA Members, A very warm welcome to the March 16th, 2016 edition of EURETINA’s web-based digital magazine, “EURETINA… Read More »March 16th, 2016: “EURETINA-Brief”© Issue No. 129
Ocugen Inc., an early stage biopharmaceutical company based in Pennsylvania, has announced the licensing of a clinical stage technology for the treatment of ocular graft… Read More »Ocugen Inc. secures license for ocular graft versus host disease (oGVHD) from Univesrity of Chicago
Recruitment to a Phase II/III trial has been initiated in the US to test the potential of an inhibitor of complement C5 (Zimura) to treat… Read More »First patient dosed in a Phase II study of the anti-C5 aptamer targeting geographic atrophy secondary to dry AMD
Research results published in the Journal of Experimental medicine (www.jem.org/cgi/doi/10.1084/jem.20150894) by scientists from Genentech’s research facilities suggest that a new molecular player in AMD may… Read More »New inhibitor against novel inflammatory target in AMD shows potential in experimental models
by Dr. Gearóid Tuohy Dear EURETINA Members, A very warm welcome to the March 2nd, 2016 edition of EURETINA’s web-based digital magazine, “EURETINA… Read More »March 2nd, 2016: EURETINA-Brief© Issue No. 128
Ocular Therapeutix Inc. (NASDAQ:OCUL), based in Bedford, Massachusetts, have announced plans for the further clinical development of a novel sustained release travoprost treatment (OTX-TP) for… Read More »Ocular Therapeutix Inc announces further clinical development studies for glaucoma and ocular hypertension treatment
A small multicentre clinical prospective study of AMD patients has suggested that intensive statin therapy may bring about a regression of large soft drusen and… Read More »Statin use appears to impact on AMD progression and visual acuity in small prospective study
Research conducted at the Regenerative Medicine Institute, Cedars-Sinai Medical Center, Los Angeles, has shown that CRISPR/Cas9 gene editing technology may be capable of correcting dominant… Read More »New CRISPR/Cas9 gene editing tool indicates a 35% visual acuity improvement in model of autosomal dominant retinitis pigmentosa
by Dr. Gearóid Tuohy Dear EURETINA Members, A very warm welcome to the February 17th, 2016 edition of EURETINA’s web-based digital magazine, “EURETINA… Read More »February 17th, 2016: “EURETINA-Brief”© Issue No. 127
The recently developed CRISPR gene editing technology is currently generating significant interest in the biomedical community, not least of all due to its low cost,… Read More »CRISPR gene editing technology continues to create significant commercial interest including applications to ophthalmology